We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for dupilumab (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
dupilumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
pre-filled syringe or pre-filled pen administered by subcutaneous injection
Indication
For the treatment of bullous pemphigoid
Therapeutic area
Dermatology